Pricing Log in Create free account
Saturday 17 October 2026 Export AMGN’s income statement to Excel — free account

Amgen Inc.

AMGN Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.

432.49 1.54 −0.35%
Market cap
$234.7B
P/E
26.7×
Fwd P/E
22.7×
Dividend yield
2.30%
F-score
7/9
Altman Z
1.69
Beneish M
−2.27
Dividend safety
56/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Amgen Inc. (AMGN) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, Amgen Inc. (AMGN) trades at a EV/Sales of 7.3×. Over the past ten years it has ranged from 4.4× (November 2016) to 8.1× (February 2024); the current reading is higher than 95% of that period. That is above the Drug Manufacturers General industry median of 4.0× and above the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 6.0× 7.13%
FY2024 5.6× (25.44%)
FY2023 7.5× 16.59%
FY2022 6.5× 9.56%
FY2021 5.9× (4.36%)
FY2020 6.2× (13.49%)
FY2019 7.1× 27.22%
FY2018 5.6× 4.23%
FY2017 5.4× 13.32%
FY2016 4.8× (16.37%)

Quarterly newest first

Period EV/Sales Change
Jun 2026 6.3× (0.81%)
Mar 2026 6.3× 4.85%
Dec 2025 6.0× 10.10%
Sep 2025 5.5× (3.63%)
42 more quarters

Against its own ten years

Low 4.4× High 8.1×
Ten-year median 6.0×
Current reading's percentile 95

EV/Sales against peers

Company EV/Sales
BMY Bristol Myers Squibb Company compare 3.1×
PFE Pfizer Inc. compare 3.5×
NVO Novo Nordisk A/S compare 3.6×
AZN AstraZeneca PLC compare 4.6×
NVS Novartis AG compare 5.8×
MRK Merck & Co., Inc. compare 6.1×
GILD Gilead Sciences, Inc. compare 7.1×
AMGN Amgen Inc. 7.3×
ABBV AbbVie Inc. compare 8.8×
Drug Manufacturers General industry median 4.0×
Healthcare sector median 3.4×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on AMGN